This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| preimplantation genetic diagnosis | |
|---|---|
| Name | Preimplantation genetic diagnosis |
| Specialty | Reproductive medicine, Medical genetics |
| Synonyms | PGD |
preimplantation genetic diagnosis is a laboratory procedure used in conjunction with In vitro fertilisation to test embryos for specific genetic, chromosomal, or mitochondrial abnormalities before uterine transfer. Developed to prevent transmission of single-gene disorders and chromosomal rearrangements, it integrates techniques from Molecular biology, Cytogenetics, and Assisted reproductive technology to enable embryo selection aimed at reducing disease burden and improving implantation outcomes. Implementation involves multidisciplinary teams drawn from Oxford University, Harvard Medical School, Cambridge University, and specialty centers such as Guy's Hospital, Monash Medical Centre, and private fertility clinics.
Origins trace to early embryology experiments at institutions like University of Cambridge and Harvard University in the 1960s and 1970s, building on the first successful In vitro fertilisation births at Oldham and District General Hospital and Bourn Hall Clinic. Pioneering work by teams at Guy's Hospital and Hammersmith Hospital led to the first clinical applications in the late 1980s and early 1990s, influenced by discoveries in Molecular biology from Cold Spring Harbor Laboratory and Max Planck Institute. Key milestones include integration of Polymerase chain reaction protocols from Stanford University laboratories and adoption of Fluorescence in situ hybridization techniques developed at University of Washington. The field expanded with contributions from researchers at University of Pennsylvania, Karolinska Institute, Imperial College London, and industry partners like Genzyme and Illumina.
Common indications include prevention of inheritance of single-gene disorders such as Huntington disease (families managed at Johns Hopkins Hospital), cystic fibrosis (centers at Massachusetts General Hospital), thalassemia (programs in National University Hospital, Singapore), and hemophilia (referrals to Mayo Clinic). Structural rearrangements and aneuploidy assessment are offered to couples with recurrent pregnancy loss managed at Stanford Health Care or recurrent implantation failure treated at Cornell University affiliated units. PGD is also used for HLA matching in families seeking a stem cell donor for a sibling treated at Great Ormond Street Hospital or Boston Children's Hospital, and for sex-linked disorders in programs at Karolinska University Hospital and Mount Sinai Hospital.
Embryo biopsy approaches evolved from cleavage-stage biopsy practiced in centers like Bourn Hall Clinic to trophectoderm biopsy in blastocyst-stage protocols developed at Monash Medical Centre and IVFMD. Molecular assays include targeted single-gene mutation analysis using techniques refined at MIT and University of Oxford, chromosomal copy-number assessment using array comparative genomic hybridization from Affymetrix collaborators, and next-generation sequencing platforms from Illumina and Thermo Fisher Scientific. Complementary methods include Karyomapping developed with input from Emory University and single-cell RNA sequencing applied in research at Broad Institute. Laboratories follow quality frameworks from College of American Pathologists and accreditation guidance from Human Fertilisation and Embryology Authority.
Accuracy depends on factors demonstrated in multicenter studies from University College London, Yale University, and University of Melbourne, including mosaicism rates, allele dropout, and amplification failure observed in single-cell PCR experiments at Sanger Institute. Trophectoderm biopsy improves concordance with inner cell mass genotypes as reported by researchers at University of Barcelona and Weill Cornell Medicine, yet false positives and false negatives remain possible, as highlighted by analyses from National Institutes of Health and European Society of Human Reproduction and Embryology. Interpretation requires integration of pedigree data, variant classification following standards from American College of Medical Genetics and Genomics, and counselling by teams at Cleveland Clinic and Guy's and St Thomas' NHS Foundation Trust.
PGD has prompted debate in forums at United Nations Educational, Scientific and Cultural Organization and policy discussions in legislatures such as the United Kingdom Parliament and United States Congress. Ethical concerns raised by bioethicists at Georgetown University, University of Toronto, and Princeton University include selection for non-medical traits, eugenics parallels discussed at Yale Law School, access disparities reported by researchers at University of Cape Town, and implications for disability communities advocated by groups linked to United Nations agencies. Legal frameworks vary, with regulatory approaches shaped by rulings in European Court of Human Rights and legislation in countries like France, Germany, and India.
Clinical outcome studies from Cornell University, University of Utah, and Monash University report improved live birth rates per transfer in some populations and reductions in transmission of targeted disorders, with long-term follow-up registries maintained by networks including ESHRE and Society for Assisted Reproductive Technology. Pediatric outcomes tracked by cohorts at University of California, San Francisco and Karolinska Institute assess developmental milestones, and epigenetic monitoring projects at Max Planck Institute for Demographic Research investigate potential imprinting effects. Psychosocial follow-up conducted by teams at King's College London and Northwestern University evaluates parental satisfaction and ethical reflections.
Regulation is country-specific: the Human Fertilisation and Embryology Authority in the United Kingdom issues licensure and guidance, while the Food and Drug Administration in the United States influences laboratory practice through oversight of related diagnostics. International guidelines and consensus statements from bodies like World Health Organization, European Society of Human Reproduction and Embryology, and International Federation of Fertility Societies inform practice standards. Policy debates involve ministries such as Ministry of Health (France), professional colleges including Royal College of Obstetricians and Gynaecologists, and patient advocacy organizations across networks in Canada and Australia.